35. Pemphigus Clinical trials / Disease details
Clinical trials : 98 / Drugs : 126 - (DrugBank : 41) / Drug target genes : 23 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04400994 (ClinicalTrials.gov) | June 20, 2020 | 27/4/2020 | IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus | The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus | Pemphigus | Drug: Rituximab;Other: IVIg | The University of Hong Kong | NULL | Recruiting | 18 Years | 70 Years | All | 20 | Phase 2 | Hong Kong |
| 2 | EUCTR2013-000211-24-DE (EUCTR) | 01/10/2013 | 08/07/2013 | immunoglobulin infusion as adjuvant therapy in patients with Pemphigus Vulgaris | A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris - IMAT-PV | patients with Pemphigus vulgaris MedDRA version: 16.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Intratect 5% Product Name: Intratect Other descriptive name: WATER FOR INJECTION Other descriptive name: GLYCINE | Ruprecht-Karls-University Heidelberg | NULL | Not Recruiting | Female: yes Male: yes | 10 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Germany | ||
| 3 | NCT00483119 (ClinicalTrials.gov) | April 2007 | 5/6/2007 | Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus | Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus | Pemphigus Vulgaris | Drug: intravenous immunoglobulin;Drug: cyclophosphamide | New York University School of Medicine | NULL | Terminated | 18 Years | 85 Years | All | 9 | Phase 2 | United States |